Back to top

Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed

$60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Lobbying related to domestic pharmaceutical supply federal budget issues"

You can find more data on corporate lobbying on Quiver Quantitative.

AMRX Hedge Fund Activity

We have seen 175 institutional investors add shares of AMRX stock to their portfolio, and 102 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

AMRX Price Targets

Multiple analysts have issued price targets for $AMRX recently. We have seen 3 analysts offer price targets for $AMRX in the last 6 months, with a median target of $17.0.

Here are some recent targets:

  • Glen Santangelo from Barclays set a target price of $16.0 on 05/20/2026
  • Ashwani Verma from UBS set a target price of $19.0 on 04/17/2026
  • Les Sulewski from Truist Securities set a target price of $17.0 on 03/02/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AMNEAL PHARMACEUTICALS, INC. (AMRX)